DSM Sinochem Pharmaceuticals
| Key drivers of profitability | Key success factors |
|---|---|
| Basic penicillin (PEN) price | Market access through global presence/alliances |
| Access to regulated markets | New technologies |
| Currency exchange rate | Access to China |
| Cost development of PEN and derivatives | Product differentiation / brand value |
| Operational excellence | |
| Access to quality-oriented customers |
DSM Sinochem Pharmaceuticals¹ (formerly DSM Anti-Infectives) is the global market leader in active pharmaceutical ingredients (APIs) such as semi-synthetic penicillins and semi-synthetic cefalosporins (beta-lactams), and other active ingredients such as nystatin, which represent the biggest class of APIs in anti-infectives.
DSM Sinochem Pharmaceuticals is also one of the few API manufacturers that continuously invest in R&D for generic antibiotics. Consequently, DSM Sinochem Pharmaceuticals manufactures nearly all its beta-lactam APIs and the related intermediates using proprietary biotechnology, which gives the company leadership in terms of both cost and sustainability as it reduces energy use and minimizes the need for solvents. Consequently emissions and costs are considerably lower than with conventional technology. The opening of the new 6-APA plant in China will mark the completion of this technology rollout across the entire global production footprint.
The APIs produced via these proprietary biotechnology routes also offer advantages in terms of increased patient safety based on the higher purity of the products, and lower spillage in the processing step from API to finished dosage form. To complete DSM Sinochem Pharmaceuticals’ enhanced eco-footprint, it is cutting down on the use of scarce resources where possible and is actively implementing the use of renewable energy sources in its operations.
1 In 2010 DSM reached agreement with Sinochem Group to form a 50/50 global joint venture for DSM Anti-Infectives with effect from 1 January 2011. A formal announcement on the launch of this joint venture, named DSM Sinochem Pharmaceuticals, was made on 31 August 2011.
